Digirad (NASDAQ:DRAD) Receives New Coverage from Analysts at Maxim Group
Maxim Group assumed coverage on shares of Digirad (NASDAQ:DRAD) in a research note issued to investors on Friday morning, AnalystRatings.com reports. The firm issued a buy rating and a $6.00 target price on the medical equipment provider’s stock.
Shares of NASDAQ DRAD opened at $2.56 on Friday. Digirad has a twelve month low of $1.99 and a twelve month high of $8.84. The stock’s 50 day moving average price is $2.67 and its 200-day moving average price is $2.95. The company has a market capitalization of $12.03 million, a PE ratio of -0.75 and a beta of 0.42. The company has a quick ratio of 1.04, a current ratio of 1.36 and a debt-to-equity ratio of 1.05.
Digirad (NASDAQ:DRAD) last announced its earnings results on Thursday, August 13th. The medical equipment provider reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $1.31. Digirad had a negative return on equity of 1.40% and a negative net margin of 5.19%. The firm had revenue of $22.34 million for the quarter.
Digirad Company Profile
Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through three segments: Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging. The Diagnostic Services segment provides nuclear and ultrasound imaging services to physicians who perform nuclear imaging, echocardiography, vascular or general ultrasound tests, imaging systems, radiopharmaceuticals, and licensing services.
See Also: Can systematic risk be avoided?
Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with MarketBeat.com's FREE daily email newsletter.